Zumilokibart Hits Primary Endpoint in APEX Part B Atopic Dermatitis Trial
Zumilokibart met the primary endpoint in Part B of the APEX atopic dermatitis trial, HCPLive reports, setting up a potential Phase 3 program for the IL-13-targeted biologic in moderate-to-severe AD.